Fake Woj (@adwojstocks) 's Twitter Profile
Fake Woj

@adwojstocks

Swing Trader/SPY options📈

ID: 1359314494112071681

calendar_today10-02-2021 01:33:36

226 Tweet

597 Takipçi

59 Takip Edilen

Fake Woj (@adwojstocks) 's Twitter Profile Photo

$HSTO check that float out. All the signs for a fast mover • .425 should be the floor • The company wants the stock to run up to $1

$HSTO check that float out. All the signs for a fast mover
• .425 should be the floor
• The company wants the stock to run up to $1
Fake Woj (@adwojstocks) 's Twitter Profile Photo

$CRTD overview -20M float -Expected to double revenue this year WITHOUT increasing operating expenses -Currently trading under last direct offering at $1.75 per share

Fake Woj (@adwojstocks) 's Twitter Profile Photo

$BBI updated DD -Enough cash for 2022 -Bunch of upcoming updates on their STING research (BBI-10) throughout 2022 -Phase 1 initiation any day now in Q2 2022; results end of 2022 - NDA filing coming for their bromide gel (ECCLOCK)

$BBI updated DD
-Enough cash for 2022 
-Bunch of upcoming updates on their STING research (BBI-10) throughout 2022
-Phase 1 initiation any day now in Q2 2022; results end of 2022
- NDA filing coming for their bromide gel (ECCLOCK)
Fake Woj (@adwojstocks) 's Twitter Profile Photo

$CNTX ▫️Four Form 4 filings 2 weeks ago equating to 125K shares at $2.19 ▫️13G filed last month for 883K shares ▫️Collabing with Memorial Sloan Kettering Cancer Center (MSK) on one of their pipeline drugs ▫️MSK is ranked #2 hopsital for cancer care in the country🔥 Zack Morris

Fake Woj (@adwojstocks) 's Twitter Profile Photo

$CNTX overview on their product ONA-XR data expected mid ‘22 🔘Being evaluated in 4(!) phase 2 trials and 2 phase 0 trials •🔘ONA-XR the only known full PR antagonist👀 🔘No current approved therapies that target (PR+) cancers so ONA-XR would be the 1st Zack Morris

Fake Woj (@adwojstocks) 's Twitter Profile Photo

$CNTX ▫️ 4 PR’s coming up this year; 3 of them regarding data ▫️NEW Menarini collab: ONA-XR + Elacestrant ➖ Elacestrant potential to be the 1st❕FDA approved oral SERD ➖Menarini was the leading italian pharm company that generated $3.9B euros in revenue🔥 Zack Morris

$CNTX
▫️ 4 PR’s coming up this year; 3 of them regarding data
▫️NEW Menarini collab: ONA-XR + Elacestrant
➖ Elacestrant potential to be the 1st❕FDA approved oral SERD
➖Menarini was the leading italian pharm company that generated $3.9B euros in revenue🔥
<a href="/MrZackMorris/">Zack Morris</a>
Fake Woj (@adwojstocks) 's Twitter Profile Photo

My ultimate $CNTX find 🔹 In 2020, Menarini acquired Stemline therapeutics (STML) for $677M 🔸STML ran over 200% after news 🔹 From website, “Menarini is also committed to oncology” 💣 my thoughts💣 If good data is presented between the 2, $CNTX is on buyout watch

Zack Morris (@mrzackmorris) 's Twitter Profile Photo

$CNTX Btw you pussstaches. I told you I liked CYCC 1.10s and look it now. You will feel so stupid when $CNTX is $5. We’re all going to laugh at you and f your girl

Fake Woj (@adwojstocks) 's Twitter Profile Photo

$SPY 15 minute close above Hugh’s 382.47 key level and I scalped 0 DTE $385 calls. You don’t get enough love for your levels thank you for sharing everyday Hugh_Henne 🐐

$SPY 15 minute close above Hugh’s 382.47 key level and I scalped 0 DTE $385 calls. You don’t get enough love for your levels thank you for sharing everyday <a href="/Hugh_Henne/">Hugh_Henne</a> 🐐
Fake Woj (@adwojstocks) 's Twitter Profile Photo

$SPY Closed out my last runner at $1.96 earlier. My biggest % gainer ever on a trade. Always learning from the best Hugh_Henne Zack Morris and applying that knowledge to these trades i take

$SPY Closed out my last runner at $1.96 earlier. My biggest % gainer ever on a trade. Always learning from the best <a href="/Hugh_Henne/">Hugh_Henne</a> <a href="/manztrades/"></a> <a href="/MrZackMorris/">Zack Morris</a> and applying that knowledge to these trades i take
Rihard Jarc (@rihardjarc) 's Twitter Profile Photo

The zero-interest rate era has, in many cases, changed the mindset of stock investors for the worse. For years, Big Tech companies didn't know what to do with their accumulated earnings and have stockpiled their balance sheets with cash or/and initiated big buyback programs and